After the discovery of cefuroxime axetil1}, a series of prodrug-type cephalosporin esters2~6) bearing 2-aminothiazole-oxime moiety at the C-7 position of a cephem nucleus have been reported as orally active cephalosporins. They are mostly characterized by various functional groups at the C-3 position.
In the course of our research on cephalosporins possessing an unique C-3 side chain, we have synthesized new 3-(l,3-dithiolan-2-yl)cephalosporins, YM-22508 (la) and YM-16457 (Id), which showed a broad antibacterial spectrum against Gram-positive and Gram-negative organisms. This paper describes the syntheses and antibacterial activities of the new cephalosporins (1) as shown in Fig. 1 .
The new 3-(l,3-dithiolan-2-yl)cephalosporins (la~lc) were prepared by the procedure shown in
was prepared as a crystalline material after stepwise protection of 7-amino-3-hydrxymethyl-3-cephem-4-carboxylic acid (2) . Swern oxidation of 3 gave the aldehyde (4). The reaction of 4 with ethanedithiol catalyzed by BF3 Et2O afforded the 3-(l,3-dithiolan-2-yl) compound (5) after deprotection by CF3COOH-anisole. Compound 5 was acylated with (Z)-2-(2-tritylamino-4-thiazolyl)-2-(l-methoxy-lmethyl)ethoxyiminoacetic acid by the acid chloride method to afford compound 7a. Removal of the pro- esters (lb and lc). Similarly, the methoxime-analogues (ld~lf) were prepared as shown in Scheme 2.
Biological Evaluation
The MICs of the new cephalosporins (la and Id) against selected Gram-positive and Gram-negative bacteria are listed in Table 18 ). For comparison, the MICvalues of cefuroxime, cefaclor and cefteram are also listed at the right side of the Table 1 . It is clearly shown that compound Id has the most balanced spectrum amongall the compounds,and the activities of compoundla against the Gram-positive test strains wereeight times as strong as that of cefteram. The in vivo antibacterial activities of 3-(l ,3-dithiolan-2-yl) derivatives (la, lc~If) against experimental infections with Staphylococcus aureus Smith, Escherichia coli NY-17and Streptococcus pyogenes S 23 are shown in Table 28 ). Although methoxime-type compounds (ld~If) had poor activities against the infection with S. aureus Smith contrary to its MICvalue, oxime-type compounds (la and lc) showed satisfactory results by subcutaneous and oral administration, respectively. The urinary and biliary recovery rates in rats by oral administration of the compounds (la~If) are listed in Table 3 . The prodrug esters of the methoxime derivative (le and If) were recovered in bile much more than in urine, while the esters of oxime derivative (1b and lc) showed an opposite tendency. Regarding the 1-acetoxyethyl esters (lc, If and cefuroxime axetil), they showed similar recovery rates in total.
Finally, we investigated the concentration of lc in plasma after oral administration to mice9). As IR spectra were taken on a Hitachi 270-30 spectrophotometer. *HNMRspectra were recorded at 90MHzon a Jeol EX-90 and at 100MHzon a Jeol EX-100 NMRspectrometer using TMSas an internal standard. MSwas measured on a Jeol JMSDX-300mass spectrometer. For column chromatography, silica gel (Kieselgel 60, Merck) was used.
Diphenylmethyl 7-terJ-Butoxycarbonylamino-3 -hydroxymethyl-3 -cephem-4-carboxylate (3) To a solution of 7-amino-3-hydroxymethyl-3-cephem-4-carboxylic acid (2, 54.0 g, 0.23 mol) and Et3N (60ml) in dioxane-water (1 : 1, 420ml) was added di-tert-butyl dicarbonate (90.8 g, 0.42mol) at room temperature. After being stirred at 30°C for 48 hours, dioxane was evaporated under reduced pressure. The residual aqueous layer was washed with EtOAc (210ml x 2) and acidified (pH 3.6) with 2n HC1. The resulting solid was collected by filtration and washed with water (100ml). The solid was then dried over P2O5 under reduced pressure to give 62.4 g of 7-te^butoxycarbonylamino-3-hydroxymethyl-3-cephem-4-carboxylic acid. This acid was dissolved in CH2C12(650 ml) and esterified with 50% diphenyldiazomethane solution in CH2C12(200ml) at 20°C for 1 hour. The reaction mixture was concentrated under reduced pressure and the residue was crystallized by adding benzene -EtOAc (3 : 1 , 120 ml). Filtration and washing of the resulting crystalline solid gave 68.5g (60%) of3: MP168-169°C; IR vmax (cm" 7-Amino-3-( l ,3-dithiolan-2-yl)-3-cephem-4-carboxylic Acid Trifluoroacetate (5) BF3 Et2O (16.8ml) was added to a mixture of 4 (49.5g, O.lOmol) and 1,2-ethanedithiol (19.0g, 0.20mol) in CH2C12(500ml) at -40°C. After being stirred at -40--30°C for 90minutes, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel eluted with benzene -EtOAc (9 : 1). The concentrated eluate was converted to a powdery solid by triturating with w-hexane -Et2O (10 : 1) to give 49. 1 g (86%) of the desired 3-(l,3-dithiolan-2-yl) derivative. To an ice-cooled mixture of the above compound (60.0g, 0.1 1 mol) and anisole (12ml) in CH2C12 (50ml) was added TFA (50ml) (
2-Methoxypropene (3.6 ml) was added to a suspension of (Z)-2-hydroxyimino-2-(2-tritylamino-4-thiazolyl)acetic acid (6a, 5.39 g, 12.5mmol) in CH2C12 (105 ml) at 10°C. The reaction mixture was stirred at room temperature for 30 minutes and concentrated under reduced pressure to dryness. The residue was dissolved in CH2C12 (75ml). PC15 (2.74g, 13.2mmol) was then added at -25°C and the mixture was stirred at -20~-15°C for 20 minutes to give a solution of (Z)-2-(l-methoxy-lmethyl)ethoxyimino-2-(2-tritylamino-4-thiazolyl)acetyl chloride.
To a suspension of 5 (3.50 g, 8.4mmol) in CH2C12 (70ml) was added bis(trimethylsilyl)acetamide (4.13ml) at 10°C. After being stirred at room temperature for 15 minutes, pyridine (3.38ml) and the solution of the previously prepared acid chloride were successively added at -65°C. The reaction mixture was stirred at -40 35°C for 30 minutes, poured into saturated aqueous KH2PO4(350 ml) and extracted with CH2C12(100 ml x 2). The combined organic extracts were washed with saturated aqueous KH2PO4 (50 ml), dried over anhydrous MgSO4and evaporated. The residue was purified by column chromatography on silica gel eluted with CHC13-2-PrOH -formic acid (100 : 
A mixture of (Z)-2-methoxyimino-2-(2-tritylamino-4-thiazolyl)acetic acid (6b, 531 mg, 1.2mmol), 1-hydroxybenzotriazole (162 mg, 1.2 mmol) and dicyclohexylcarbodiimide (250 mg, 1.2 mmol) in dioxane (10 ml) was stirred at room temperature for 30 minutes. The reaction mixture was filtered to give a solution of the corresponding activated ester. The filtrate was added to a solution of 5 (304mg, 0.7mmol) and NaHCO3(178mg, 2.1 mmol) in water (4ml). After being stirred at room temperature overnight, the mixture was concentrated under reduced pressure. The residue was treated with saturated aqueous NaHCO3 (5 ml) and washed with EtOAc (20 ml x 2). The aqueous layer was then extracted with methyl ethyl ketone after acidification (pH 1) with 2n HC1. The organic layer was washed with brine, dried over anhydrous MgSO4and evaporated. The residue was triturated with 2-Pr2O (15ml) to give 444mg (84%) of 7b: IR vmax (cm"1) 3360-3240, 1775, 1665; XH NMR (DMSO-J6) 8 
A solution of pivaloyloxymethyl chloride (40mg, 0.3 mmol) in DMF(l ml) was added to a solution of la (113mg, 0.2mmol) and K2CO3 (18mg, 0.1 mmol) in DMF (5ml) at -10°C. The mixture was then stirred at -10-2°C for 20 hours. After removal of solvent under reduced pressure, Et2O (5 ml) was added to the residue. The resulting powder was filtered and purified by column chromatography eluted with Determination of Antibacterial Activity APR. 1991 MICs (//g/ml) were determined by the standard 2-fold agar dilution method in Mueller-Hinton agar after incubation at 37°C for 18 hours with an inoculum size of 106 cfu/ml.
Antibacterial activity in vivo was tested using male mice (ICR, 4~5 weeks old, n-6). Mice were individually given an antibiotic suspension in 0.5% methyl cellulose subcutaneously or orally 2 hours after the bacterial challenge. ED50 values (mg/kg) were calculated by the probit method for the number of mice surviving 7 days after infection.
Urinary and biliary excretion were tested using male rats (SD, 7 weeks old, n = 3). The test compounds were administered orally to rats at a dose of 50mg/kg. Urinary and biliary recovery rates (%) were calculated from the urinary and biliary concentrations of drugs at 0 to 24 hours after administration. Concentrations were determined by bioassay (agar well method) using E. coli NIHJ as a test organism.
